SCHEMBL6820702

SCHEMBL6820702

CCOCCOc1cc2ccc(-c3ccc(Cl)s3)cc2cc1C1=NCCN1

nearest known ligand 0.38

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 3/20 0.38
PDCD1LG2 Q9BQ51 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
S1PR1 P21453 1/20 0.35
NCF1 P14598 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6824784 0.91 NISCH (0.42) NISCHPDCD1LG2CD274PDGFRBPDGFRA
SCHEMBL6825093 0.91 NISCH (0.42) NISCHPDCD1LG2CD274PDGFRBPDGFRA
Hydrochloric Acid SCHEMBL7736901 0.87 NISCH (0.40) NISCHPDCD1LG2CD274PDGFRBPDGFRA
SCHEMBL6826512 0.83 NISCH (0.43) NISCHPDCD1LG2CD274S1PR1
Hydrochloric Acid SCHEMBL7736145 0.82 NISCH (0.42) NISCHPDCD1LG2CD274S1PR1
Hydrochloric Acid SCHEMBL7738760 0.81 VCP (0.40) PDGFRBPDGFRANCF1
Hydrochloric Acid SCHEMBL8336601 0.79 NISCH (0.39) NISCHPDCD1LG2CD274PDGFRBPDGFRA
Hydrochloric Acid SCHEMBL8189621 0.79 LMNA (0.37) NISCHPDGFRBPDGFRAS1PR1
SCHEMBL6824880 0.76 NISCH (0.46) NISCHPDCD1LG2CD274
SCHEMBL6826683 0.75 NISCH (0.36) NISCHPDCD1LG2CD274PDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885PDCD1LG2 4073/4885CD274 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.